Mitoxantrone Terminated Phase 1 Trials for Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Alkylating Agent-Related Acute Myeloid Leukemia / Adult Acute Basophilic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Minimal Differentiation / Untreated Adult Acute Myeloid Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Adult Acute Megakaryoblastic Leukemia / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Monoblastic Leukemia / Secondary Acute Myeloid Leukemia (Secondary AML, sAML) / Adult Acute Myelomonocytic Leukemia / Adult Acute Myeloid Leukemia With Maturation Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01260714Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia